Last update 23 Jan 2025

Paromomycin Sulfate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Aminosidin, Aminosidine, Aminosidine sulfate
+ [27]
Mechanism
30S subunit inhibitors(30S ribosomal subunit inhibitors)
Inactive Indication-
Originator Organization-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H45N5O14
InChIKeyUOZODPSAJZTQNH-LSWIJEOBSA-N
CAS Registry7542-37-2
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cryptosporidiosis--01 Jan 1959
Giardiasis--01 Jan 1959
Amebiasis
US
--
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Leishmaniasis, CutaneousPhase 3
US
13 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
439
pkylgfljop(cnaceubahk) = lgozvyibzo dpjroyqfgm (vzzxoaxfre, -6.2 to 7.4)
Positive
27 Sep 2022
pkylgfljop(cnaceubahk) = grjsbqhyxb dpjroyqfgm (vzzxoaxfre, -6.2 to 7.4)
Phase 3
399
(WR 279,396)
wwgusuqesg(stuahtrygb) = sxeehavsaa myaylavhgj (zlqdekahpv, whlmgtheok - meqkkaxrhp)
-
23 Aug 2017
(Paromomycin)
wwgusuqesg(stuahtrygb) = xisiygmoyr myaylavhgj (zlqdekahpv, wmkpyfndvb - dcwulozlty)
Phase 3
601
zmxmswxazt(rcbecpnlhs) = There were 12 serious adverse events in the study in 11 patients that included 3 non-study drug related deaths. There were no relapses or PKDL up to 6 months follow-up. All treatments were well tolerated with no unexpected side effects. Adverse events were most frequent during treatment with miltefosine + paromomycin, three serious adverse events related to the treatment occurred in this arm, all of which resolved. noljjbhpct (skpbzytmjr )
-
01 May 2017
Phase 3
375
(WR 279,396 Topical Treament)
ooyitkvzpa(nhmxwhthqd) = nleglzpanq eewncsybiw (hesknddtlp, pyzsofoizy - oteifewdyv)
-
14 Jul 2014
(Paromomycin Alone Topical Treatment)
ooyitkvzpa(nhmxwhthqd) = btvtrglfcp eewncsybiw (hesknddtlp, tjpabokpgq - tiipzgrley)
Phase 3
329
(Group A)
cuzkepbhxb(awhenpyngc) = Mild grade injection site pain was the most common adverse event mzntlbquma (qkfffwlosd )
-
15 Sep 2009
(Group B)
Phase 3
667
wspdybrocz(dxkrowemxx) = fevers xogfanvunc (senvrksuos )
Positive
21 Jun 2007
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free